{
    "clinical_study": {
        "@rank": "88951", 
        "acronym": "Ca_Pulmon", 
        "brief_summary": {
            "textblock": "This is a national, multicentre, non-interventional, retrospective study to be carried out\n      in the oncology settings of approximately 15-20 Spanish hospitals.\n\n      At each participant hospital, all patients recently diagnosed with advanced EGFR mutated\n      NSCLC (both newly or with recurrent disease , without previous treatment for metastatic\n      disease) from April 2010 to December 2011 will be included as study population. Information\n      about the follow-up of the patients during a minimum of 12 months after diagnosis will be\n      collected."
        }, 
        "brief_title": "Retrospective Study in a NSCLC M+ p", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "EGFR Mutated Non-small Cell Lung Cancer Patients", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Observational retrospective study to describe the management of advanced or metastatic EGFR\n      mutated non-small cell lung cancer patients in Spain"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed newly locally advanced or metastatic NSCLC\n             (stage IIIB/IV)\n\n          -  Confirmed EGFR mutation by a validated test\n\n          -  Availability of medical record\n\n        Exclusion Criteria:\n\n          -  Participating on a blinded randomized clinical trial at any time during the study\n             period\n\n          -  Pregnant women (due to they do not reflect daily clinical practice)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All patients recently diagnosed with advanced EGFR mutated NSCLC (both newly or with\n        recurrent disease , without previous treatment for metastatic disease) from April 2010 to\n        December 2011 will be included as study population."
            }
        }, 
        "enrollment": {
            "#text": "187", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01795352", 
            "org_study_id": "NIS-OES-XXX-2012/1"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "EGFR,", 
            "lung cancer,", 
            "mutated"
        ], 
        "lastchanged_date": "October 29, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cordoba", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Donostia", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Granada", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leon", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Malaga", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Navarra", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toledo", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zaragoza", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_groups": "1", 
        "official_title": "Observational Retrospective Study to Describe the Management of Advanced or Metastatic EGFR (Epidermal Growth Factor Receptor) Mutated Non-small Cell Lung Cancer Patients in Spain", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Spain: Spanish Agency of Medicines", 
                "Spain: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Description of management patterns (clinical and diagnostic) of advanced/metastatic EGFR M+ NSCLC patients in Spain.", 
            "safety_issue": "No", 
            "time_frame": "32 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01795352"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Description of use of resources related with the management of advanced/metastatic EGFR M+ NSCLC patients in Spain.", 
                "safety_issue": "No", 
                "time_frame": "32 months"
            }, 
            {
                "measure": "Evaluation of overall response rate (ORR).", 
                "safety_issue": "No", 
                "time_frame": "32 months"
            }, 
            {
                "measure": "Evaluation of disease control rate (DCR).", 
                "safety_issue": "No", 
                "time_frame": "32 months"
            }, 
            {
                "measure": "Evaluation of progression free survival (PFS: median PFS and 1 year PFS rate).", 
                "safety_issue": "No", 
                "time_frame": "32 months"
            }, 
            {
                "measure": "Evaluation of overall survival (OS: median OS and 1 year OS rate).", 
                "safety_issue": "No", 
                "time_frame": "32 months"
            }, 
            {
                "description": "TK- Tyrosine Kinase", 
                "measure": "Description of clinical outcome data in all EGFR M+ patients by regimen, type of EGFR TK mutation, line of therapy and other relevant demographics or clinic pathologic characteristics.", 
                "safety_issue": "No", 
                "time_frame": "32 months"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}